Oral GLP-1 - SinoDrugWatch

Oral Semaglutide

Novo Nordisk Secures First Oral GLP-1 Cardiovascular Approval in EU

Novo Nordisk’s Rybelsus® is now the first oral GLP-1 RA approved in Europe with cardiovascular benefit, following positive SOUL trial results. This milestone reshapes the GLP-1 landscape, combining oral convenience with outcomes data, and may accelerate adoption in China’s type 2 diabetes market.

naperiglipron

Naperiglipron Trial Terminations Highlight Shifts in Oral GLP-1 Market

Eli Lilly stopped two Phase 2 trials of naperiglipron after minimal enrollment, citing strategic reasons. Development continues in obesity, but structural similarity to Pfizer’s failed compounds raises safety scrutiny.

Oral GLP-1

China’s Oral GLP-1 Surge: Rising Amid Global Setbacks and Intensifying Competition

China surges in the oral GLP-1 race: 25+ assets (HRS-7535, HDM1002) and key Merck, Madrigal & AstraZeneca deals set up a 2026–27 shakeup. Novo’s oral semaglutide nears approval (16.6% WL), Lilly’s orforglipron shows mixed Phase 3 (12% WL in obesity, 10.5% WL + 1.8% HbA1c in T2D), Pfizer exits.